Review





Similar Products

drug infusion cannulae targeting hvc terminals  (Protech Technology Enterprise)
86
Protech Technology Enterprise drug infusion cannulae targeting hvc terminals
Drug Infusion Cannulae Targeting Hvc Terminals, supplied by Protech Technology Enterprise, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drug infusion cannulae targeting hvc terminals/product/Protech Technology Enterprise
Average 86 stars, based on 1 article reviews
drug infusion cannulae targeting hvc terminals - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
drug target genes prognostic genes  (Human Protein Atlas)
86
Human Protein Atlas drug target genes prognostic genes
Drug Target Genes Prognostic Genes, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drug target genes prognostic genes/product/Human Protein Atlas
Average 86 stars, based on 1 article reviews
drug target genes prognostic genes - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
her2 targeting affibody drug conjugates  (Affibody)
86
Affibody her2 targeting affibody drug conjugates
Her2 Targeting Affibody Drug Conjugates, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/her2 targeting affibody drug conjugates/product/Affibody
Average 86 stars, based on 1 article reviews
her2 targeting affibody drug conjugates - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
market target linker drug moiety brentuximab seattle  (Pfizer Inc)
86
Pfizer Inc market target linker drug moiety brentuximab seattle
Market Target Linker Drug Moiety Brentuximab Seattle, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/market target linker drug moiety brentuximab seattle/product/Pfizer Inc
Average 86 stars, based on 1 article reviews
market target linker drug moiety brentuximab seattle - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
drug target interactions  (Molecular Dynamics Inc)
86
Molecular Dynamics Inc drug target interactions
Drug Target Interactions, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drug target interactions/product/Molecular Dynamics Inc
Average 86 stars, based on 1 article reviews
drug target interactions - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
fda approved drug targets  (Human Protein Atlas)
86
Human Protein Atlas fda approved drug targets
Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
Fda Approved Drug Targets, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fda approved drug targets/product/Human Protein Atlas
Average 86 stars, based on 1 article reviews
fda approved drug targets - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
monoclonal antibody drug targeting il 36r  (Boehringer Ingelheim)
86
Boehringer Ingelheim monoclonal antibody drug targeting il 36r
Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
Monoclonal Antibody Drug Targeting Il 36r, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal antibody drug targeting il 36r/product/Boehringer Ingelheim
Average 86 stars, based on 1 article reviews
monoclonal antibody drug targeting il 36r - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
fdaapproved drug targets  (Human Protein Atlas)
86
Human Protein Atlas fdaapproved drug targets
Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
Fdaapproved Drug Targets, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fdaapproved drug targets/product/Human Protein Atlas
Average 86 stars, based on 1 article reviews
fdaapproved drug targets - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
drug target identification  (Molecular Dynamics Inc)
86
Molecular Dynamics Inc drug target identification
Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
Drug Target Identification, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drug target identification/product/Molecular Dynamics Inc
Average 86 stars, based on 1 article reviews
drug target identification - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
affibody derived drug conjugates targeting her2 effect  (Affibody)
86
Affibody affibody derived drug conjugates targeting her2 effect
Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
Affibody Derived Drug Conjugates Targeting Her2 Effect, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/affibody derived drug conjugates targeting her2 effect/product/Affibody
Average 86 stars, based on 1 article reviews
affibody derived drug conjugates targeting her2 effect - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets of FDA-approved drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.

Journal: eBioMedicine

Article Title: Identification and validation of an 11-kinase signature that predicts chemo- and radiosensitivity in gastric cancer

doi: 10.1016/j.ebiom.2026.106154

Figure Lengend Snippet: Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets of FDA-approved drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.

Article Snippet: Given the distinct molecular features observed for the EMT and metabolism subgroups, we mined FDA-approved drug targets from the Human Protein Atlas to identify subgroup-selective therapeutic targets.

Techniques: Expressing, Quantitative Proteomics, Fluorescence, In Situ, Hybridization, Gene Expression